SCHOLAR ROCK HOLDING CORPORATION Earnings Per Share, Basic and Diluted
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Earnings Per Share, Basic and Diluted of -$0.84 per share for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-10.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2021-08-10
- SCHOLAR ROCK HOLDING CORPORATION earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.84.
- SCHOLAR ROCK HOLDING CORPORATION earnings per share, basic and diluted for the quarter ending 2021-03-31 was -$0.76.
- SCHOLAR ROCK HOLDING CORPORATION earnings per share, basic and diluted for the quarter ending 2020-12-31 was -$0.78.
- SCHOLAR ROCK HOLDING CORPORATION earnings per share, basic and diluted for the quarter ending 2020-09-30 was -$0.79.
- SCHOLAR ROCK HOLDING CORPORATION earnings per share, basic and diluted for fiscal 2020 was -$2.81.
- SCHOLAR ROCK HOLDING CORPORATION earnings per share, basic and diluted for fiscal 2019 was -$1.85.
- SCHOLAR ROCK HOLDING CORPORATION earnings per share, basic and diluted for fiscal 2018 was -$3.15.
- SCHOLAR ROCK HOLDING CORPORATION earnings per share, basic and diluted for fiscal 2017 was -$15.30.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2021-06-30 | -$0.84 10-Q · filed 2021-08-10 | -$1.60 10-Q · filed 2021-08-10 | -$2.38 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$3.18 derived: net income ÷ weighted average shares · filed 2022-11-14 |
| 2021-03-31 | -$0.76 10-Q · filed 2021-05-13 | -$1.54 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$2.33 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$2.99 derived: net income ÷ weighted average shares · filed 2022-11-14 |
| 2020-12-31 | -$0.78 derived: net income ÷ weighted average shares · filed 2022-03-07 | -$1.57 derived: net income ÷ weighted average shares · filed 2022-03-07 | -$2.23 derived: net income ÷ weighted average shares · filed 2022-03-07 | -$2.81 10-K · filed 2021-03-09 |
| 2020-09-30 | -$0.79 10-Q · filed 2020-11-09 | -$1.44 derived: net income ÷ weighted average shares · filed 2021-11-09 | -$2.02 10-Q · filed 2020-11-09 | -$2.42 derived: net income ÷ weighted average shares · filed 2021-11-09 |
| 2020-06-30 | -$0.65 10-Q · filed 2021-08-10 | -$1.23 10-Q · filed 2021-08-10 | -$1.62 derived: net income ÷ weighted average shares · filed 2021-11-09 | -$2.18 derived: net income ÷ weighted average shares · filed 2021-11-09 |
| 2020-03-31 | -$0.58 10-Q · filed 2021-05-13 | -$0.97 derived: net income ÷ weighted average shares · filed 2021-11-09 | -$1.52 derived: net income ÷ weighted average shares · filed 2021-11-09 | -$2.01 derived: net income ÷ weighted average shares · filed 2021-11-09 |
| 2019-12-31 | -$0.39 derived: net income ÷ weighted average shares · filed 2021-03-09 | -$0.95 derived: net income ÷ weighted average shares · filed 2021-03-09 | -$1.43 derived: net income ÷ weighted average shares · filed 2021-03-09 | -$1.85 10-K · filed 2021-03-09 |
| 2019-09-30 | -$0.55 10-Q · filed 2020-11-09 | -$1.04 derived: net income ÷ weighted average shares · filed 2020-11-09 | -$1.46 10-Q · filed 2020-11-09 | -$2.06 derived: net income ÷ weighted average shares · filed 2020-11-09 |
| 2019-06-30 | -$0.48 10-Q · filed 2020-08-07 | -$0.90 10-Q · filed 2020-08-07 | -$1.51 derived: net income ÷ weighted average shares · filed 2020-11-09 | -$1.95 derived: net income ÷ weighted average shares · filed 2020-11-09 |
| 2019-03-31 | -$0.42 10-Q · filed 2020-05-07 | -$1.02 derived: net income ÷ weighted average shares · filed 2020-11-09 | -$1.47 derived: net income ÷ weighted average shares · filed 2020-11-09 | -$2.40 derived: net income ÷ weighted average shares · filed 2020-11-09 |
| 2018-12-31 | -$0.61 derived: net income ÷ weighted average shares · filed 2020-03-12 | -$1.05 derived: net income ÷ weighted average shares · filed 2020-03-12 | -$2.04 derived: net income ÷ weighted average shares · filed 2020-03-12 | -$3.15 10-K · filed 2020-03-12 |
| 2018-09-30 | -$0.44 10-Q · filed 2019-11-12 | -$1.46 derived: net income ÷ weighted average shares · filed 2019-11-12 | -$2.72 10-Q · filed 2019-11-12 | |
| 2018-06-30 | -$1.39 10-Q · filed 2019-08-14 | -$3.51 10-Q · filed 2019-08-14 | ||
| 2018-03-31 | -$3.18 10-Q · filed 2019-05-15 | |||
| 2017-12-31 | -$15.30 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |